Dec. 5 at 2:56 AM
$GANX imo we should all hope for acquisition. If their data is good they will raise money off it, no matter what. The CEO hinted as much in that interview w Lou. He said "we'll need them if we have to fund our own phase 2" referring to institutional biotech investors and large family offices, said they were being shown data in "real time." That could cause shares to fall after a pop or at least cap them for the time being.
They'll raise money so they can get better terms on any negotiation w BP. You have to be able to show BP you are willing to go it alone and have the funding to do so in order to get your terms. Unless of course your drug is THAT special, then BP pays up. Will they do that for a phase 1B drug? You never know, and you never know what GANX would accept, but it's doubtful. Regardless, I'm hoping the data is that compelling where someone decides to just but the company for
$15 or
$20 a share and the board signs off on it and we're done. One can dream....
